Developers
Compare launch barriers across evidence, payment, delivery, and access workstreams.
Road to Access guides
Cited guideAccess
Country Launch-Readiness Scorecard Methodology
How Blossom reads country-level evidence, access, reimbursement, delivery, ecosystem, and source-review signals when interpreting launch readiness.
- Dimensions
- 6
- Readout
- Bands
- Access
- Pro
Evidence, pathway, reimbursement, delivery, ecosystem, source review
Qualitative bands avoid false precision and global ranking claims
Full scorecards are paid strategic-review pages
At a glance
What to take from this page
- The scorecards use a common framework with country-specific interpretation.
- Unknown areas stay visible rather than being hidden or treated as penalties.
- The scorecards support strategic review; they are not legal, medical, reimbursement, or investment advice.
Who this helps
Investors
Separate visible readiness signals from unresolved country-level implementation risk.
Access teams
Keep source strength, evidence gaps, and review status visible when country coverage is incomplete.
Launch readiness
Approval is only one lane in the launch system
Each lane needs an owner, cited assumptions, and a concrete path into routine care before a positive decision can become patient access.
Evidence
1Clinical / HEOR
Endpoint, comparator, durability, safety, resource use
HTA
2Market access
Model, uncertainty plan, patient selection, value story
Payment
3Payer / provider
Drug, service, monitoring, registry, and site-cost object
Sites
4Operations
Rooms, pharmacy, escalation, referral, contracting
Workforce
5Clinical governance
Training, supervision, protected time, medical cover
Data
6Evidence operations
Baseline, follow-up, relapse, retreatment, adverse events
Governance
7Provider leadership
Protocol, consent, audit, quality assurance, accountability
Equity
8Payer / policy
Eligibility, geography, wait lists, private spillover
Scorecard dimensions
| Dimension | What it reads | Typical support signal |
|---|---|---|
| Evidence and research activity | Whether country-linked trials and active studies suggest a visible evidence base. | Trial counts, active-study signal, compounds, topics |
| Access pathway clarity | Whether medical, regulatory, or special-access routes are visible enough to interpret. | Access axes, regulatory context, policy items |
| Reimbursement and payment | Whether public, private, self-pay, or institutional payment routes are visible. | Payment axis, reimbursement notes, compound access status |
| Delivery capacity | Whether the system has plausible sites, workforce, governance, or care infrastructure. | Stakeholders, subnational reports, medical-access signals |
| Local ecosystem | Whether researchers, organizations, events, and resources indicate local activity. | Stakeholder counts, events, Road to Access country resources |
| Source review | How current and reviewed the underlying Blossom interpretation is. | Source-review level, last reviewed date, visible gaps |
The dimensions are interpreted together. A strong signal in one lane does not cancel an unknown or not-reviewed signal in another lane.
Source posture
| Posture | Meaning | How to read it |
|---|---|---|
| Cited source | A reviewed source or access-axis field directly supports the statement. | Use as stronger support, while still checking review date and source coverage. |
| Blossom records | The statement comes from linked Blossom counts or records. | Read as Blossom coverage, not a claim of complete national activity. |
| Blossom review | Blossom combines signals into a practical access or readiness judgment. | Use for orientation and follow-up questions, not as a final decision. |
A framework, not a country ranking
The scorecard framework is designed to make country-level launch-readiness signals easier to scan. It does not produce a definitive global order of countries.
Each country is read across a shared set of dimensions, then interpreted with visible source-review notes and caveats. Better Blossom coverage should not be confused with higher country readiness.
Germany shows why dimensions have to stay separate
Germany has a strong esketamine reimbursement precedent, a homegrown psilocybin evidence base through EPIsoDE, and a BfArM-listed psilocybin compassionate-use program. Those are meaningful signals.
They do not add up to routine classic-psychedelic access. Payment for therapy time, site expansion, compassionate-use renewal after July 2026, and controlled-substance operations still need separate review.
How to read readiness bands
The overall band compresses dimension-level signals into a short label. It should always be read together with the dimension cards, review status, and gaps.
High readiness means several dimensions have strong signals and no obvious limited dimension in the current Blossom view. Emerging readiness means multiple dimensions are moving but still need review. Watch or constrained means some launch workstreams remain limited. Incomplete evidence means too many dimensions are unknown or not reviewed to support a readiness interpretation.
Source review and unknown areas
Source review describes how much current, reviewed country and access information supports the interpretation. It is separate from readiness: limited source review does not automatically mean a country is less ready, and strong source review does not automatically mean a country is launch-ready.
Unknown areas protect the page from over-claiming. They should trigger follow-up research rather than being read as evidence of absence.
Limits of use
The scorecards are strategic intelligence for product, access, and implementation planning. They are not legal, clinical, reimbursement, or investment advice.
Country systems change. Users should verify current law, reimbursement, provider readiness, and local implementation requirements before making launch or access decisions.